MSJ BioTech secures tens of millions in funding to lead new frontier of AI-driven recombinant collagen medical devices

Meishangjie Biotechnology Co., Ltd. ("MSJ Biotech") announced the successful completion of a new tens of millions of yuan Series A+ financing round. This round was jointly led by Jiaxing Sumin Hongxi Venture Capital Partnership (Limited Partnership) and Originvest (Guolian Financial Investment Zhiyuan (Jiangsu) Private Equity Fund Management Co., Ltd).

The raised funds will be primarily used to accelerate R&D investment in genetic engineering and synthetic biology, advance the clinical translation and market expansion of its recombinant humanized collagen products, and continuously optimize its technology platforms. The company also plans to establish a new Class III medical device production pipeline in Yixing. Additionally, several other investment institutions are actively participating in follow-on investments, with tens of millions of yuan still available in the current round.

The funds raised in this round will be used to further accelerate the company's R&D investment in the field of genetic engineering and synthetic biology, promote the clinical transformation and market expansion of its recombinant humanized collagen protein products, and continuously optimize its technical platform. The plan is to establish a new Class III medical device production line in Yixing. In addition, there are tens of millions of follow-on investments in this round, and several other investment institutions are still actively following up.

Mr. Zhao Hua, CEO of Meishangjie Biotechnology, stated: "We are truly honored to receive the recognition and support from these two highly reputable investment institutions. Since its establishment in 2018, Meishangjie Biotechnology has consistently focused on the field of genetic engineering and synthetic biotechnology, achieving breakthrough progress particularly in the R&D and medical applications of recombinant humanized collagen products. The success of this financing round not only affirms our existing achievements and future potential but also strongly validates our commitment to technological innovation. We will seize this opportunity to further intensify R&D efforts, accelerate product commercialization, and deliver safer, more effective solutions for the healthcare sector."

The core competitiveness of MSJ BioTech lies in its innovative technology platform. As a leading Chinese company in AI-driven development of recombinant fusion proteins, it has successfully utilized AI modeling to achieve diversified editing of sequence fragments and implemented large-scale synthetic biology fermentation and extraction. This has enabled the establishment of an advanced recombinant humanized protein technology platform, which ensures the efficient and stable production of high-quality recombinant humanized collagen, laying a solid foundation for the company's future product development.

Currently, MSJ BioTech's product pipeline includes both Class II and Class III medical devices, with some products already in the clinical stage. These products hold broad application prospects, covering indications in multiple critical clinical departments such as plastic surgery, dermatology, general surgery, burn care, and orthopedics, and are expected to bring transformative improvements across various medical specialties.

The follow-on investment phase of this financing round remains ongoing. MSJ BioTech is actively engaging with potential follow-on investors to further strengthen its capital base, thereby providing robust support for the company's long-term development and strategic objectives.